The NIH: A Budget Appraisal

Digital Vision President George W. Bush's decision to halt historic increases in the National Institutes of Health budget in fiscal year 2004 raises questions about how much the agency and the researchers it funds should expect to receive in the coming years. With a possible war on the horizon, the economy in a slump, and dreams of future federal surpluses fading, policymakers and scientists suggest that funding other science-related agencies may be a higher priority. Beltway observers also q

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

President George W. Bush's decision to halt historic increases in the National Institutes of Health budget in fiscal year 2004 raises questions about how much the agency and the researchers it funds should expect to receive in the coming years. With a possible war on the horizon, the economy in a slump, and dreams of future federal surpluses fading, policymakers and scientists suggest that funding other science-related agencies may be a higher priority. Beltway observers also question whether NIH researchers, accustomed to ample funds, should have been better prepared for the inevitable buck in the funding trend.

"This has been forecast from day one, five years ago," says Martin Apple, president of the Council of Scientific Society Presidents. "The question is what have we done to adapt to it. And if the answer is 'nothing,' then it's partially our problem as well as everybody else's."

GOOD FOR THE GANDER President ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Eugene Russo

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo